Literature DB >> 34725177

Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement.

Alfredo Aguirre1, Jinoos Yazdany2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34725177      PMCID: PMC9068232          DOI: 10.3899/jrheum.211000

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   5.346


× No keyword cloud information.
  24 in total

Review 1.  Hepatitis B virus epidemiology.

Authors:  Jennifer H MacLachlan; Benjamin C Cowie
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

3.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.

Authors:  Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2008-09-19

4.  The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.

Authors:  Christopher R Holroyd; Rakhi Seth; Marwan Bukhari; Anshuman Malaviya; Claire Holmes; Elizabeth Curtis; Christopher Chan; Mohammed A Yusuf; Anna Litwic; Susan Smolen; Joanne Topliffe; Sarah Bennett; Jennifer Humphreys; Muriel Green; Jo Ledingham
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

Review 5.  Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-03-27

Review 6.  Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

Authors:  Adrian M Di Bisceglie; Anna S Lok; Paul Martin; Norah Terrault; Robert P Perrillo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

7.  Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.

Authors:  Blanca Sampedro; Cándido Hernández-López; José Ramón Ferrandiz; Aitziber Illaro; Emilio Fábrega; Antonio Cuadrado; Paula Iruzubieta; Susana Menéndez; Joaquín Cabezas; Javier Crespo
Journal:  Hepatology       Date:  2014-05-28       Impact factor: 17.425

8.  Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis.

Authors:  Alexander Lawandi; Matthew P Cheng; Todd C Lee
Journal:  PLoS One       Date:  2019-07-08       Impact factor: 3.240

9.  Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration.

Authors:  A Jasmine Bullard; Francesca E Cunningham; Bryan D Volpp; Elliott Lowy; Lauren A Beste; Bernadette B Heron; Mark Geraci; Julia M Hammond; Kourtney LaPlant; Elise A Stave; Marsha J Turner; Meghan C O'Leary; Michael J Kelley; Christine M Hunt
Journal:  Hepatol Commun       Date:  2018-08-28

Review 10.  Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.

Authors:  Christos Koutsianas; Konstantinos Thomas; Dimitrios Vassilopoulos
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-03-16       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.